Developing precision medicines to target the cells driving organ scarring
Fibrosis is the build-up of scar tissue after injury and can progressively impair organs, including the liver. The cells and molecular pathways driving this damage create a need for treatments that target the underlying disease processes rather than the consequences of organ dysfunction.
Forth Therapeutics is developing precision medicines for fibrotic diseases. It analyses patient tissue using single-cell and spatial genomics to identify harmful cell populations and drug targets, aiming to create targeted treatments for organ scarring.
What stands out about Forth Therapeutics
Spun out of the University of Edinburgh to translate Neil Henderson’s fibrosis and tissue-regeneration research into precision medicines.
Co-founder Alex Leech led Creabilis Therapeutics as CEO through its acquisition by Sienna Biopharmaceuticals in 2016.
Founder Neil Henderson is an MD/PhD and honorary consultant hepatologist, combining clinical practice with research into organ fibrosis.
Launched through Sofinnova’s Biovelocita biotech accelerator, combining Edinburgh research with specialist company-building support.
Alex Leech was Alchemab Therapeutics' founding CEO, leading it from inception through its Series A financing.
Alex Leech previously held CEO roles at biotechnology companies Camphos and Zarodex, before leading Forth Therapeutics.
Neil Henderson is an MD/PhD and Edinburgh Chair of Tissue Repair and Regeneration whose research focuses on the mechanisms driving organ fibrosis.
Uses multi-omic analysis of patient-derived tissue samples to identify cellular targets and develop precision therapies for fibrotic disease.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.